Abstract. Background: Dengue virus (DENV) still poses a global public health threat, and no vaccine or antiviral therapy is currently available. Antibody plays distinct roles in controlling DENV infections. Neutralizing antibody is protective against DENV infection, whereas sub-neutralizing concentration of antibody can increase DENV infection, termed antibody-dependent enhancement (ADE). Plaque-based assay represents the most widely accepted method measuring neutralizing or enhancing antibodies. Results: In this study, a novel reporter virus-based system was developed for measuring neutralization and ADE activity. A stable Renilla luciferase reporter DENV (Luc-DENV) that can produce robust luciferase signals in BHK-21 and K562 cells were used to establish the assay and validated against traditional plaque-based assay. Luciferase value analysis using various known DENV-specific monoclonal antibodies showed good repeatability and a well linear correlation with conventional plaque-based assays. The newly developed assay was finally validated with clinical samples from infected animals and individuals. Conclusions: This reporter virus-based assay for neutralizing and enhancing antibody evaluation is rapid, lower cost, and high throughput, and will be helpful for laboratory detection and epidemiological investigation for DENV antibodies.
- Dengue virus
- Enhancing antibody
- Luciferase assay
- Neutralizing antibody
ASJC Scopus subject areas
- Microbiology (medical)
A novel reporter system for neutralizing and enhancing antibody assay against dengue virus. / Song, Ke Yu; Zhao, Hui; Jiang, Zhen You; Li, Xiao Feng; Deng, Yong Qiang; Jiang, Tao; Zhu, Shun Ya; Shi, Pei-Yong; Zhang, Bo; Zhang, Fu Chun; Qin, E. De; Qin, Cheng Feng.In: BMC Microbiology, Vol. 14, No. 1, 44, 18.02.2014.
Research output: Contribution to journal › Article